The FDA gives the green light to the first gene therapy for deafness
The treatment, developed by Regeneron Pharmaceuticals, is for a very rare form of deafness. But it represents a medical milestone.
DeafMonitor aggregates Deaf-community news and credits every story to its original publisher. This story was reported by NPR.
Read the full story at NPR
Read the full story at NPR